[REVISION HISTORY]

Brazil expands public cancer screening and oncology care

Updated 5 times since CLSTR started tracking revisions of this situation.

What changed

2026-08-27 19:47 UTC → 2026-09-03 11:44 UTC · added ~~removed~~

In July 2026, Brazil announced new guidelines prioritizing molecular HPV testing with self-collection to replace the Pap smear, aiming to increase participation and reduce disparities in cervical cancer screening. Implementation has already begun in locations such as Piancó, Paraíba, where DNA-HPV molecular tests are being offered to women aged 25–64. To support these efforts, legislative proposal Bill 969/26 has been introduced, seeking to make the HPV vaccine mandatory and formalize the Unified Health System’s (SUS) transition to molecular testing as the primary screening method. Authored by Deputy Fausto Jr., Bill 969/26 also aims to expand healthcare access to rural, riverside, and indigenous communities through the use of mobile units. This push for modernization coincides with recognition of scientific contributions, such as scientist Luisa Lina Villa receiving the Octavio Frias de Oliveira Prize for her research establishing the link between HPV and various cancers. By late August 2026, new data from Hospital Moinhos de Vento in Porto Alegre has validated the effectiveness of vaccination efforts. A study of over 16,000 young people aged 16 to 25 showed that the prevalence of vaccine-targeted HPV types among women dropped from 15.64% to 5.92%. While vaccination coverage in Rio Grande do Sul has reached 80.63% for girls and 72.86% for boys, researchers note these figures remain below the 90% target for girls under 14 established by the World Health Organization. Concurrently, the public health system in the Distrito Federal has detailed a comprehensive breast cancer early-detection pathway, offering free mammograms for women aged 40 to 75. In early September 2026, the Rio Branco Municipal Health Secretariat began implementing a molecular testing program for cervical cancer screening in Acre. Currently in a pilot phase at the Augusto Hidalgo de Lima Primary Care Reference Unit, the initiative uses DNA-HPV oncogenic testing to detect high-risk human papillomavirus.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.